low dose of glp 1 GLP-1 microdosing is popular, but there's little evidence it works GLP-1 Medications: Everything You Need

however, if the risk of MASLD is linked with declining circulating E2 levels, MASLD risk would not be expected to increase in early perimenopause where E2 levels do not consistently fall and may even periodically rise above premenopausal levels (see Fig

Sermorelin : A growth hormone-releasing hormone (GHRH) analog, Sermorelin also stimulates the release of GH from the pituitary gland

Studies on free radicals, antioxidants, and co-factors

Protocols vary, but many clinics structure treatment in cycles of several weeks to a few months, with periodic reassessment to determine whether to continue, taper, or discontinue therapy